# Agent Capital

> Agent Capital is a Waltham, Massachusetts healthcare venture firm that invests directly in differentiated therapeutics and enabling technologies from preclinical work through commercial scaling. Founded in 2016 by Geeta Vemuri and Preston Noon, it combines scientific diligence with drug-development, licensing, financing and operating experience, concentrating on oncology, immunology, neurology and rare disease.

- **Founded:** 2016
- **Headquarters:** Waltham, United States
- **Founders:** Geeta Vemuri (Managing Partner, Founder), Preston Noon (Partner, Co-Founder)
- **Team size:** Approximately 16 people in supplied company data; the public LinkedIn page lists a 2-10 employee range, while the company site includes core investors, operating partners, finance staff and advisers.
- **Products:** Direct equity investment, Portfolio guidance, Healthcare venture funds
- **Notable:** Named the Penn Center for Innovation's 2025 Paul D. Sehnert Memorial Partner of the Year., Portfolio company DICE Therapeutics was acquired by Eli Lilly for approximately $2.4 billion in 2023., Portfolio company Interius BioTherapeutics was acquired by Kite, a Gilead company, for $350 million in 2025.

## Products & services

- **Direct equity investment** — Capital for healthcare and biotechnology companies across preclinical, clinical and commercial stages and across financing-round types.
- **Portfolio guidance** — Hands-on support around development milestones, financing strategy, portfolio management, business development and paths to exit.
- **Healthcare venture funds** — Pooled investment vehicles for limited partners seeking specialist exposure to therapeutics and enabling life-science technologies.

## Achievements

- Named the Penn Center for Innovation's 2025 Paul D. Sehnert Memorial Partner of the Year.
- Portfolio company DICE Therapeutics was acquired by Eli Lilly for approximately $2.4 billion in 2023.
- Portfolio company Interius BioTherapeutics was acquired by Kite, a Gilead company, for $350 million in 2025.
- Portfolio company ImCheck Therapeutics was acquired by Ipsen in 2025 for €350 million upfront and up to €1 billion including milestones.
- The public portfolio includes multiple listed companies, including Metagenomi, Pyxis Oncology, Q32 Bio and Zenas BioPharma.

## Latest updates

- **2026-07** — Portfolio company Freenome announced FDA approval of its SimpleScreen colorectal-cancer blood test and an Abbott commercialization arrangement in the United States.
- **2026-07** — Freenome debuted as a publicly traded company focused on blood-based early cancer detection.
- **2026-01** — Alveus Therapeutics launched with a $160 million Series A to advance obesity and metabolic-disease therapies.
- **2025-12** — Penn Center for Innovation named Agent Capital its Partner of the Year.
- **2025-12** — Ipsen completed its acquisition of portfolio company ImCheck Therapeutics.

## Links

- Website: https://www.agentcapital.com/
- LinkedIn: https://www.linkedin.com/company/agentcapital/

---

Profile page: https://yespress.io/agent-capital
Published by YesPress — https://yespress.io
Last updated: 2026-08-17